ID   MEGAL
AC   CVCL_1833
DR   ArrayExpress; E-MTAB-7721
DR   ArrayExpress; E-MTAB-7722
DR   Cosmic; 787451
DR   Cosmic; 975269
DR   Cosmic; 1012088
DR   Cosmic; 1281327
DR   Cosmic; 2306218
DR   Cosmic; 2588711
DR   DSMZ; ACC-719
DR   DSMZCellDive; ACC-719
DR   Wikidata; Q54905040
RX   PubMed=16408098;
RX   PubMed=19166587;
RX   PubMed=31160637;
CC   Part of: LL-100 blood cancer cell line panel.
CC   Doubling time: ~70 hours (DSMZ=ACC-719).
CC   HLA typing: A*11:01:01,11:01:01; B*07:02:01,07:02:01; C*07:02:01,07:02:01; DPA1*02:01:02,02:01:02; DPB1*01:01:01,01:01:01; DQB1*06:02:01,06:02:01; DRA*01:02:03,01:02:03; DRB1*15:01:01,15:01:01 (DSMZCellDive=ACC-719).
CC   Sequence variation: Gene fusion; HGNC; 8064; NUP214 + HGNC; 10760; SET; Name(s)=SET-NUP214 (PubMed=19166587).
CC   Omics: Deep exome analysis.
CC   Omics: Transcriptome analysis by RNAseq.
ST   Source(s): DSMZ=ACC-719
ST   Amelogenin: X
ST   CSF1PO: 10,12
ST   D13S317: 12
ST   D16S539: 11
ST   D18S51: 13,14
ST   D19S433: 13,16
ST   D21S11: 28,30
ST   D2S1338: 17,25
ST   D3S1358: 15,17
ST   D5S818: 9,12
ST   D7S820: 11,12
ST   D8S1179: 12
ST   FGA: 20,23
ST   Penta D: 9,10
ST   Penta E: 14
ST   TH01: 9.3
ST   TPOX: 9
ST   vWA: 16
DI   NCIt; C3170; Acute megakaryoblastic leukemia
DI   ORDO; Orphanet_518; Acute megakaryoblastic leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 19
//
RX   PubMed=16408098; DOI=10.1038/sj.leu.2404081;
RA   Quentmeier H., MacLeod R.A.F., Zaborski M., Drexler H.G.;
RT   "JAK2 V617F tyrosine kinase mutation in cell lines derived from
RT   myeloproliferative disorders.";
RL   Leukemia 20:471-476(2006).
//
RX   PubMed=19166587; DOI=10.1186/1756-8722-2-3;
RA   Quentmeier H., Schneider B., Rohrs S., Romani J., Zaborski M.,
RA   MacLeod R.A.F., Drexler H.G.;
RT   "SET-NUP214 fusion in acute myeloid leukemia- and T-cell acute
RT   lymphoblastic leukemia-derived cell lines.";
RL   J. Hematol. Oncol. 2:3.1-3.5(2009).
//
RX   PubMed=31160637; DOI=10.1038/s41598-019-44491-x;
RA   Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M.,
RA   MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.;
RT   "The LL-100 panel: 100 cell lines for blood cancer studies.";
RL   Sci. Rep. 9:8218-8218(2019).
//